Author

Willem de Villiers 1

1 University of Stellenbosch, Stellenbosch, South Africa

A POOLED SAFETY ANALYSIS FROM THE USTEKINUMAB CROHN?S DISEASE AND PSORIATIC DISEASES PHASE 2 AND 3 CLINICAL TRIAL PROGRAMS

Subrata Ghosh, Bruce E. Sands, Willem de Villiers, Elyssa Ott, Christopher Gasink, Yinghua Lang, Philippe Szapary, Douglas Jacobstein, Brian G. Feagan

EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN'S DISEASE THROUGH 5 YEARS: FINAL RESULTS FROM THE IM-UNITI LONG-TERM EXTENSION

William Sandborn, Paul Rutgeerts, John Lynch, Rory Rebuck, Yuhua Wang, Bin Zou, Christopher Gasink, Omoniyi J. Adedokun, Bruce E. Sands, Stephen B Hanauer, Stephan Targan, Subrata Ghosh, Willem de Villiers, Jean-Frederic Colombel, Brian G. Feagan

EFFICACY AND SAFETY OF USTEKINUMAB FOR CROHN'S DISEASE: RESULTS FROM IM-UNITI LONG-TERM EXTENSION THROUGH 3 YEARS

William Sandborn, Paul Rutgeerts, Douglas Jacobstein, Christopher Gasink, Rishit Patel, Bin Zou, Jewel Johanns, Bruce E. Sands, Stephen B Hanauer, Stephan Targan, Subrata Ghosh, Willem de Villiers, Jean-Frederic Colombel, Brian G. Feagan

Identification of risk factors associated with loss of response to ustekinumab in Crohn's disease

Steve Hanauer, Bruce E. Sands, Brian G. Feagan, A Oortwijn, Roger van Kruchten, Victor Laliman, James Izanec, Joseph Adedokun, Long-Long Gao, Sheldon Sloan, Christopher Gasink, S Targan, Willem de Villiers, Paul Rutgeerts, Jean-Frédéric Colombel, Subrata Ghosh

Immunogenicity of Ustekinumab in Patients with Crohn's Disease: Results from the IM-UNITI Study

William Sandborn, Bruce E. Sands, Jeannette Nussbaum, A Oortwijn, Christopher Gasink, Douglas Jacobstein, Long-Long Gao, Omoniyi J. Adekokun, Willem de Villiers, Subrata Ghosh

Item 1 - 5 / 5
1